Organogenesis Holdings Inc
NASDAQ:ORGO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BetterLife Pharma Inc
CNSX:BETR
|
CA |
|
Inmobiliaria Colonial SOCIMI SA
MAD:COL
|
ES |
Organogenesis Holdings Inc
Long-Term Debt
Organogenesis Holdings Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Organogenesis Holdings Inc
NASDAQ:ORGO
|
Long-Term Debt
$12.8m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Debt
$58.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
7%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Long-Term Debt
$22.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
0%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Long-Term Debt
$50B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Long-Term Debt
$106.7m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-18%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Long-Term Debt
$2.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
22%
|
|
Organogenesis Holdings Inc
Glance View
Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 950 full-time employees. The company went IPO on 2016-12-02. Its solutions address comorbidities such as diabetes, obesity, cardiovascular and peripheral vascular disease, and smoking. The wound care products include Apligraf for the treatment of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs); Dermagraft for the treatment of diabetic foot ulcer (DFU); PuraPly AM and PuraPly XT as antimicrobial barriers for variety of wound types; and the Affinity and NuShield wound coverings to address a variety of wound sizes and types. Its surgical and sports medicine product includes ReNu for in-office knee osteoarthritis treatment; NuCel for bony fusion in the lumbar spine; NuShield and Affinity barrier products for surgical application in targeted soft tissue repairs; and PuraPly AM for management of open wounds in the surgical setting.
See Also
What is Organogenesis Holdings Inc's Long-Term Debt?
Long-Term Debt
12.8m
USD
Based on the financial report for Dec 31, 2025, Organogenesis Holdings Inc's Long-Term Debt amounts to 12.8m USD.
What is Organogenesis Holdings Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
-28%
Over the last year, the Long-Term Debt growth was 1 681%. The average annual Long-Term Debt growth rates for Organogenesis Holdings Inc have been -42% over the past three years , -28% over the past five years .
